Supernus Pharma (NASDAQ: SUPN) reported Q1 EPS of $0.49, $0.16 better than the analyst estimate of $0.33. Revenue for the quarter came in at $90 million versus the consensus estimate of $85.29 million.

• Total revenue of $90.4 million, a 57% increase over 2017
• Net product sales of $89.1 million, a 58% increase over 2017
• Operating earnings of $31.4 million, an 87% increase over 2017
• Diluted earnings per share (GAAP) of $0.49, compared to $0.19 in 2017

Financial Guidance

For full year 2018, the Company reiterates its prior guidance for net product sales, research and development expenses, operating earnings, and effective tax rate as set forth below:

• Net product sales in the range of $375 million to $400 million.
• Research and development expenses of approximately $80 million.
• Operating earnings in the range of $125 million to $135 million, including approximately $7 million of licensing and non-cash royalty revenue.
• Effective tax rate of approximately 23% to 25%.

GUIDANCE:

Supernus Pharma sees FY2017 revenue of $375-400 million, versus the consensus of $398.5 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.